Xconomy Health Tech
Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases.
“When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head of Johnson & Johnson (NYSE: JNJ) External Innovation, told delegates at the BIO-Europe Spring event, held digitally last week due to the coronavirus crisis.
While there have been notable exceptions—particularly in the cardiovascular diseases where Hait said it was realized early on that decreasing... Read more »
Pharma and software firms are actively embracing AI and machine learning, but governments may need to lead the way in accessing relevant data, says Molecular Health.
Molecular Health, a software firm focused on transforming big data into analysis and prediction tools for healthcare companies, believes biotech is in the early days of using artificial intelligence (AI) and machine learning in drug discovery and development.
It is not the technology available holding the industry back, but the managing and the monitoring of the data involved, according to Molecular Health CEO Friedrich von Bohlen.
“In certain parts of the process we can [embrace... Read more »